Dear Reader,

As we approach the end of 2016, and publish our final issue of Drugs—Real World Outcomes for the year, we wish to reflect on another successful year for the journal and for others in the Adis Premier journals portfolio, and to thank all who have contributed to Drugs—Real World Outcomes over the past 12 months.

An important milestone was reached for Drugs—Real World Outcomes in that the journal content is now available on PubMed Central. Another of our open access journals, Drug Safety—Case Reports, is also now available on PubMed Central.

As of September 2016, Drugs—Real World Outcomes’ top 10 downloaded articles from SpringerLink this year were:

We offer our sincere thanks to all authors who have contributed articles to Drugs—Real World Outcomes over the course of 2016. Their skill and dedication are critical to the continued publication of the journal. The quality of published articles is, similarly, testament to the significant efforts of the peer reviewers, whose commitment ensures that the journal’s content is held to the highest possible standard. We would like to thank the following individuals who acted as reviewers for Drugs—Real World Outcomes in the last 12 months:

Adebowale Dele Ademola, Nigeria

Kraemer Alwin, Germany

Richard H. Aster, USA

Pierrick Bedouch, France

Nancy Bernardy, USA

Benoit Boland, Belgium

Machaon Bonafede, USA

Neil Brickel, UK

Marta Brooks, USA

Anette Bygum, Denmark

Johanna Callhoff, Germany

Wendy Cheng, USA

Victoria Collings, UK

Rohan A. Elliott, Australia

Barbara Farrell, Canada

Paula Fresco, Portugal

Masahiro M. Fukuoka, Japan

Chris Gillette, USA

B. Joseph Guglielmo, USA

Zeky Yüksel Gunaydin, Turkey

Mark Haggard, UK

Jesper Hallas, Denmark

Mainul Haque, Malaysia

Swapnil Hiremath, Canada

Keith B. Hoffman, USA

Chun-Ta Huang, Taiwan

Klejda Hudhra, Spain

Sekwon Jang, USA

Susan Jick, USA

Pravin Kamble, USA

Harparkash Kaur, UK

Donald G. Klepser, USA

Paul T. Kocis, USA

Sam Kosari, Australia

Richard Laing, USA

Cecilie Johannessen Landmark, Norway

Marianne Lisby, Denmark

Eleanor Lucas, USA

Hendrika Luijendijk, The Netherlands

Anke H. Maitland-van der Zee, The Netherlands

Louise Mallet, Canada

G. B. John Mancini, Canada

Gloria Manso, Spain

John F. McCarthy, USA

Natalie McCormick, Canada

Anthony B. Miller, Canada

Andrew Mosholder, USA

Domenico Motola, Italy

Marco Mula, UK

Giorgio Mustacchi, Italy

Paul N. Newton, UK

Onyema Ogbuagu, USA

Jan Palmblad, Sweden

Jean-Jacques Parienti, France

Timo Partonen, Finland

Kathryn Peri, New Zealand

Sathirakorn Pongpanich, Thailand

Valentin Prieto-Centurion, USA

Neal Ready, USA

Jenna M. Reps, UK

John Robst, USA

Albert Roger, Spain

Josea Rono, Kenya

Sabine Ruths, Norway

Alan Schorr, USA

Todd Semla, USA

Pasquale Striano, Italy

Roger E. Thomas, Canada

Philippe Thuillier, France

Petra A. Thurmann, Germany

James E. Tisdale, USA

Giuliano Tocci, Italy

Antonella Tosti, USA

Robert Vander Stichele, Belgium

Bastiaan Venhuis, The Netherlands

Pa-Chun Wang, Taiwan

Juanita Westbury, Australia

Peter K.K. Wong, Australia

Antoinette A. Wozniak, USA

In addition, we would like to thank the members of the journal’s Honorary Editorial Board, who have acted as peer reviewers and authors, and have provided guidance on journal content, policy and processes:

G.C. Alexander, Johns Hopkins University, Baltimore, MD, USA

A. Beresniak, Data Mining International, Geneva, Switzerland

M.L. Berger, Pfizer, Inc., New York, NY, USA

H. Birnbaum, Analysis Group, Inc., Boston, MA, USA

J.M. Bottomley, Amygdala Ltd., Letchworth Garden City, England

P. Denig, University of Groningen, Groningen, The Netherlands

J.E. Fincham, Presbyterian College School of Pharmacy, Clinton, SC, USA

B. Godman, Karolinska Institutet, Stockholm, Sweden

D. Goldsmith, Goldsmith Pharmacovigilance and Systems, New York, NY, USA

S. Karve, AstraZeneca, Gaithersburg, MD, USA

N.Y. Kirson, Analysis Group, Inc., Boston, MA, USA

C. Kozma, CK Consulting Associates, St. Helena Island, SC, USA

T. Lasky, MIE Resources, Baltimore, MD, USA

A.A. Mangoni, Flinders University, Adelaide, SA, Australia

S. Mimica-Matanovic, University Hospital Osijek, Osijek, Croatia

A. Modi, Merck, Whitehouse Station, NJ, USA

J.K. Sluggett, Monash University, Parkville, VIC, Australia

K.A. Swanson, University of Oklahoma, Oklahoma City, OK, USA

J.E Ware Jr., University of Massachusetts, Worcester, MA, USA

Q. Zou, The Lewin Group, Falls Church, VA, USA

In other portfolio news, mid-2016 saw the release of the ISI Journal Citation Reports and the latest journal impact factors. The majority of our journals saw a rise in impact factor against the previous year. Most notably, five of our journals saw an increase of over 10% in impact factor – The Patient (17.08%), Clinical Drug Investigation (15.99%), the American Journal of Clinical Dermatology (13.17%), Drug Safety (13.5%), and Drugs (12.43%).

The Adis journals portfolio will expand in 2017, with the launch of PharmacoEconomics—Open. This new journal will be fully open access and will focus on the publication of applied research on the economic implications and health outcomes associated with drugs, devices and other healthcare interventions. It joins our other well respected health outcomes publications, PharmacoEconomics, Applied Health Economics and Health Policy, and The Patient: Patient-Centered Outcomes Research.

We hope that you have found the articles published throughout 2016 to be both interesting and informative. We have appreciated the high quality of content contributed to the journal this year and look forward to keeping you up to date with topical real-world outcomes in 2017.

With best wishes from Dene Peters (Editor-in-Chief) and Kathy Fraser (Deputy Editor).